MannKind Corporation Share Price Nasdaq
Equities
US56400P2011
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-08 | Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05 | MT |
Sales 2024 * | 272M 21.74B | Sales 2025 * | 319M 25.43B | Capitalization | 1.18B 93.92B |
---|---|---|---|---|---|
Net income 2024 * | 35M 2.79B | Net income 2025 * | 70M 5.59B | EV / Sales 2024 * | 3.41 x |
Net cash position 2024 * | 248M 19.83B | Net cash position 2025 * | 273M 21.77B | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
37.6
x | P/E ratio 2025 * |
19.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.48% |
Latest transcript on MannKind Corporation
Managers | Title | Age | Since |
---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 47 | 13/03/16 |
Sanjay Singh
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/09/22 |
Kevin Kaiserman
CTO | Chief Tech/Sci/R&D Officer | - | 30/08/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | 26/11/18 | |
Anthony Hooper
BRD | Director/Board Member | 69 | 31/12/19 |
Ronald Consiglio
BRD | Director/Board Member | 80 | 30/09/03 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |